Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIIa (NovoSeven/NiaStase) in severely injured trauma patients with refractory bleeding
2005-002059-41Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-traumatic hemorrhage comparing rFVIIa (NovoSeven/NiaStase) plus standard care with Placebo plus standard care (2 arms). Started Jun 2005; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
post-traumatic hemorrhage
Beyond the preview
Go deeper on 2005-002059-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002059-41.